MDIs and dry powder inhalers: Maximizing benefits, avoiding pitfalls

Consultant

Volumn 40, Issue 3, 2000, Pages 501-509

  Dhand, Rajiv ^a,b,c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLAVORING AGENT; PROPELLANT; SOLVENT; SURFACTANT; THEOPHYLLINE;

AEROSOL; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; INHALATION; METERED DOSE INHALER; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SAFETY; THRUSH;

EID: 0034028615     PISSN: 00107069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. June D. A new generation of inhaler technology. Br J Clin Pract. 1995;79(suppl):18-21.
2. Dhand R, Malik SK, Balakrishan M, Verma SK. High speed photographic analysis of aerosols produced by metered-dose inhalers. J Pharm Pharmacol. 1988;40:429-430.
3. Newman SP, Pavia D, Moren F, et al. Deposition of pressurized aerosols in the human respiratory tract. Thorax. 1981;36:52-55.
4. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest. 1985;88(suppl):S153-S160.
5. Epstein SW, Manning CPR, Ashley MJ, Corey PN. Survey of the clinical use of pressurized aerosol inhalers. CMAJ. 1979;120:813-816.
6. De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung disease. Am Rev Respir Dis. 1989;140:910-916.
7. Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med. 1994;150:1256-1261.
8. Thompson J, Irvine T, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest. 1994;105:715-717.
9. Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992;146:1559-1564.
10. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled medications. Arch Intern Med. 1994;154:1349-1352.
11. Crompton GK, Duncan J. Clinical assessment of a new breath-actuated inhaler. Practitioner. 1989;233: 268-269.
12. Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax. 1991;46:712-716.
13. Dolovich M. Characterization of medical aerosols: physical and clinical requirements for new inhalers. Aerosol Sci Technol. 1995;22:392-399.
14. O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drugs. Thorax. 1993;48:603-606.
15. Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the bioavailability of salbutamol via a spacer device. Thorax. 1996;51:981-984.
16. Wildhaber JH, Devadason SG, Hayden MJ, et al. Electrostatic charge on plastic spacer devices influences the delivery of salbutamol. Eur Respir J. 1996;9:1943-1946.
17. Hansen OR, Pederson S. Optimal inhalation technique with terbutaline Turbuhaler. Eur Respir J. 1989;2:637-639.
18. Engel T, Heinig JK, Madsen F, Nikander K. Peak inspiratory flowrate and inspiratory vital capacity of patients with asthma measured with and without a new dry powder inhaler device (Turbuhaler). Eur Respir J. 1990;3:1037-1041.
19. Pederson S, Hansen OR, Fuglsang G. Influence of inspiratory flowrate upon the effect of a Turbuhaler. Arch Dis Child. 1990;65:308-310.
20. Duncan D, Paterson IC, Harris D, Crompton GK. Comparison of the bronchodilator effects of salbutamol inhaled as a dry powder and by conventional pres-surized aerosol. Br J Clin Pharmacol. 1977;4:669-671.
21. Thorsson L, Edsbacke S, Conradson TB. Lung deposition from Turbuhaler is twice that from a pressurized metered-dose inhaler (pMDI). Eur Respir J. 1994;7:1839-1844.
22. Svartengren K, Lindestad PA, Svartengren M, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med. 1995;152:32-37.
23. Dolovich M, Vanzieleghem M, Hidinger KG, Newhouse MT. Influence of inspiratory flow rate on the response to terbutaline sulphate inhaled via the Turbuhaler. Allergy Proc. 1988;9:380-382.
24. Tonnesen T, Laursen LC, Ibsen T, et al. Terbutaline powder in acute bronchial obstruction. Lancet. 1993;337:1099-1100.
25. Rajkumari NJ, Byron PR, Dalby RN. Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharm. 1995;113:123-130.